•  
  •  
 

Abstract

The acceleration of technological change, public policy, economic forces, and increased collaboration between research institutions and industrial sponsors has dramatically increased potential conflicts of interest (COIs) in collaborative clinical trials (CCTs). This paper includes a short history of CCTs and describes the forces affecting public policy and increased collaboration and COIs. Current methods of identifying and addressing COIs will be described, as well as the shortcomings of these methods. Finally, a new, fully-transparent model for addressing COIs will be presented which protects human research subjects, end-users of technologies, and the scientific integrity in the clinical trials process.

Share

COinS